美国HIV感染者与非感染者他汀起始治疗发生率的前瞻性观察研究
该研究基于多中心AIDS队列研究和妇女机构间HIV研究,随访842名男性和852名女性(均有2013年ACC/AHA指南他汀起始指征),评估2年内他汀起始发生率。结果显示仅20%参与者在指征出现后2年内报告他汀使用,HIV状态间无显著差异,但黑人较非黑人起始率更低(男性14.0% vs 22.3%)。
要点
- 有他汀指征者2年内仅20%报告他汀使用,指南驱动的起始率低。
- 他汀起始率在HIV感染者与非感染者间无显著差异。
- 黑人男性起始率14.0% vs 非黑人男性22.3%,差异-8.3%(95%CI -13.8%至-2.8%)。
核心结论
- 指南驱动的他汀起始率低,且存在显著的种族差异。
- 随着HIV感染者他汀使用指征扩大,解决指南实施的障碍对改善结局至关重要。
研究设计与样本
- 前瞻性观察研究,使用多中心AIDS队列研究(MACS)和妇女机构间HIV研究(WIHS)数据。
- 随访842名男性和852名女性,均有基于2013年ACC/AHA指南的他汀起始指征,随访期为2014年1月至2020年3月。
- 按人口学、临床和行为特征分层估计2年他汀起始发生率,并使用发生率差进行比较。
主要发现
- 在出现他汀指征后2年内,20%的参与者报告他汀使用。
- 他汀起始率在HIV感染者与非感染者间无显著差异。
- 黑人男性他汀起始率14.0% vs 非黑人男性22.3%,差异-8.3%(95%CI -13.8%至-2.8%)。
- 仅基于10年预测ASCVD风险≥7.5%有指征者中,他汀起始率男性14.2%、女性15.2%;已有ASCVD者中男性32.9%、女性22.0%;糖尿病患者中男性26.4%、女性24.5%。
- 当前吸烟者较非当前吸烟者他汀起始率更低,有合并症者他汀起始率更高。
关键数值与推荐
- 他汀起始指征基于2013年ACC/AHA指南。
- 2年内他汀起始率总体为20%。
- 黑人男性他汀起始率14.0% vs 非黑人男性22.3%,差异-8.3%(95%CI -13.8%至-2.8%)。
- 仅基于10年预测ASCVD风险≥7.5%有指征者中,他汀起始率男性14.2%、女性15.2%;已有ASCVD者中男性32.9%、女性22.0%;糖尿病患者中男性26.4%、女性24.5%。
临床怎么用
- 对于有他汀指征的HIV感染者,应关注指南驱动的他汀起始率低的问题。
- 需关注黑人患者他汀起始的种族差异。
- 随着HIV感染者他汀指征扩大,解决指南实施障碍对改善结局至关重要。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To reduce atherosclerotic cardiovascular disease (ASCVD) among US people with human immunodeficiency virus (HIV, PWH), it is critical to assess shortfalls in statin initiation. We aimed to describe patterns in clinically indicated statin initiation among demographically similar people with or at increased vulnerability to HIV. METHODS: Using data from the Multicenter AIDS Cohort Study and Women's Interagency HIV Study, we followed 842 men and 852 women with an indication for statin use based on 2013 American College of Cardiology/American Heart Association guidelines for statin initiation between January 2014 and March 2020. We estimated 2-year incidence of statin initiation stratified by demographic, clinical, and behavioral characteristics and compared estimates using incidence differences. RESULTS: Within 2 years of statin indication, 20% of participants reported statin use. Initiation of statin therapy did not differ significantly by HIV status. However, initiation was lower among Black versus non-Black persons, especially among men (14.0% versus 22.3%; difference, -8.3%; 95% confidence interval, -13.8% to -2.8%). Compared with initiation among persons indicated based only on ≥7.5% 10-year predicted ASCVD risk (incidence: men, 14.2%; women, 15.2%), initiation was higher among those with existing ASCVD (incidence: men, 32.9%; women, 22.0%) or diabetes (incidence: men, 26.4%; women, 24.5%). Initiation was lower among current versus noncurrent smokers and higher among those with comorbidities. CONCLUSIONS: Guideline-driven statin initiation was low, with large inequities by race. With indications for statin use expanding for PWH, redressing barriers to guideline implementation will be crucial to achieving improved outcomes through uptake of these evidence-based therapies.
引用
- Breger TL, Westreich DJ, Edmonds A, et al. Incidence of Statin Initiation Among People With and Without HIV in the United States: A Prospective Observational Study. Clin Infect Dis. 2025. PMID: 40244915. doi:10.1093/cid/ciaf207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。